Outcomes Insights Team
Dr. Danese’s expertise is in the design and analysis of studies using observational data, creation of budget impact and cost-effectiveness models, and the design of population-based simulation models. He has over 50 peer-reviewed manuscripts published in journals including JAMA, Blood, Journal of Bone and Mineral Research, Cancer, American Journal of Kidney Diseases, Value in Health, and the Journal of Clinical Endocrinology and Metabolism.
Dr. Danese is a collaborator with the Observational Health Data Science and Informatics (OHDSI) collaborative, helping to develop open-source tools to improve the conduct of observational studies. He is also a member of the following organizations: the American Statistical Association, Academy Health, the Society for Medical Decision Making, the International Society for Pharmacoepidemiology, the American Medical Informatics Association, and the International Society for Pharmacoeconomics and Outcomes Research.
direct line: +1.805.498.0034
Ms. Duryea’s current projects at Outcomes Insights include building economic models, data analysis, and medical data research, including medical coding and analyzing payer policies. Ms. Duryea is also a frequent contributor to the OHDSI community, where she has helped develop ETL documents for various datasets and provided expertise on OHDSI’s vocabulary development.
direct line: +1.805.367.7481
In recent years, he created an open-source language (ConceptQL) that unambiguously defines and structures a set of criteria in a flexible, easily parse-able, and human readable, format to serve as a foundation for the Jigsaw suite of tools. He is also a regular contributor to several projects in the OHDSI community
direct line: +1.805.367.7486
Her client engagements include mobile health and telemedicine solutions, innovation in personalized medicine and diagnostics, health IT and hospital solutions, and product portfolio strategies. Her therapeutic areas include neurology, psychiatry, gastroenterology, endocrinology, oncology, anti-infectives, respiratory, nephrology and women’s health. Previously, she was a Director at Amgen, a VP at Migliara/Kaplan (now Kantar Health), an Officer at the FDA aligned with the Division of Neuropharmacological Drug Products, and a Sales Rep for Eli Lilly. She has a BS in Chemistry from The University of Virginia and an MBA from Darden.